Los Angeles Capital Management
FHTX icon

Los Angeles Capital Management’s Foghorn Therapeutics FHTX Stock Holding History

Los Angeles Capital Management’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-27,099
Closed -$127K – 1418
2025
Q2 		$127K Buy
27,099
+11,225
+71% +$46.9K ﹤0.01% 1237
2025
Q1 		$57.9K Buy
15,874
+23
+0.1% +$105 ﹤0.01% 1072
2024
Q4 		$74.8K Buy
+15,851
New +$115K ﹤0.01% 1091

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Los Angeles Capital Management's FHTX Position: Q3 2025 in Review

Los Angeles Capital Management sold out of Foghorn Therapeutics (FHTX) in Q3 2025, closing a stake of 27,099 shares — an estimated $127K sold.

Los Angeles Capital Management first reported a position in FHTX in Q4 2024 and held it in 3 quarters. The position peaked at $127K in Q2 2025. 88 funds tracked by Wall St. Rank hold FHTX as of Q3 2025.

  • Los Angeles Capital Management reported no remaining Foghorn Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Los Angeles Capital Management sold 27,099 Foghorn Therapeutics shares in Q3 2025, an estimated $127K.
  • Los Angeles Capital Management first reported a position in Foghorn Therapeutics in Q4 2024 and held it in 3 quarters.
  • Los Angeles Capital Management's Foghorn Therapeutics position peaked at $127K in Q2 2025.
  • 88 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q3 2025.

Based on Los Angeles Capital Management's 13F filing for Q3 2025, filed 20 Oct 2025.